IFP Advisors
TRDA icon

IFP Advisors’s Entrada Therapeutics TRDA Stock Holding History

IFP Advisors’s Portfolio TRDA Stock Details TRDA Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q3 		$2.13K Buy
336
+165
+96% +$1.14K ﹤0.01% 4199
2026
Q2 		$1.26K Buy
171
+170
+17,000% +$1.63K ﹤0.01% 4426
2026
Q1 		$13 Buy
+1
New +$11 ﹤0.01% 4950
2025
Q4 		– Sell
-2
Closed -$12 – 5037
2025
Q3 		$12 Buy
+2
New +$12 ﹤0.01% 4779
2025
Q2 		– Sell
-64
Closed -$515 – 4403
2025
Q1 		$579 Sell
64
-23
-26% -$287 ﹤0.01% 3427
2024
Q4 		$1.5K Buy
+87
New +$1.58K ﹤0.01% 3185

Other funds holding TRDA

China Universal Asset Management Company
China Universal Asset Management Company Shanghai, China $1.92B AUM 74.14% 1-Year Est. Return
Harbor Capital Advisors
Harbor Capital Advisors Chicago, Illinois $1.48B AUM 30.88% 1-Year Est. Return
Wealth Enhancement Advisory Services
Wealth Enhancement Advisory Services Plymouth, Minnesota $67.3B AUM 21.9% 1-Year Est. Return
STRS Ohio
STRS Ohio Columbus, Ohio $27.1B AUM 34.64% 1-Year Est. Return
Versant Capital Management
Versant Capital Management Phoenix, Arizona $1.17B AUM 28.44% 1-Year Est. Return
State of Wyoming
State of Wyoming Cheyenne, Wyoming $1.29B AUM 32.25% 1-Year Est. Return
Nisa Investment Advisors
Nisa Investment Advisors St. Louis, Missouri $34.7B AUM 25.93% 1-Year Est. Return
Mirae Asset Global Investments
Mirae Asset Global Investments Seoul, South Korea $57B AUM 43.56% 1-Year Est. Return
GF Fund Management
GF Fund Management Guangzhou, China $7.72B AUM 122.96% 1-Year Est. Return
SJS Investment Consulting
SJS Investment Consulting Sylvania, Ohio $993M AUM 16.29% 1-Year Est. Return

IFP Advisors's TRDA Position: Q3 2026 in Review

IFP Advisors increased its Entrada Therapeutics (TRDA) stake by 96% in Q3 2026, buying an estimated $1.14K and bringing the position to 336 shares worth $2.13K. The position accounts for ﹤0.01% of the portfolio, ranked #4199.

IFP Advisors first reported a position in TRDA in Q4 2024 and has held it in 6 quarters since. 23 funds tracked by Wall St. Rank hold TRDA as of Q3 2026.

  • IFP Advisors held 336 shares of Entrada Therapeutics worth $2.13K as of Q3 2026.
  • IFP Advisors bought 165 Entrada Therapeutics shares in Q3 2026, an estimated $1.14K.
  • Entrada Therapeutics made up ﹤0.01% of IFP Advisors's portfolio in Q3 2026, its #4199 holding.
  • IFP Advisors first reported a position in Entrada Therapeutics in Q4 2024 and has held it in 6 quarters since.
  • 23 funds tracked by Wall St. Rank held Entrada Therapeutics as of Q3 2026.

Based on IFP Advisors's 13F filing for Q3 2026, filed 16 Oct 2026.